Crossmark

Testing and Treating Small Intestinal Bacterial Overgrowth Reduces Symptoms in Patients with Inflammatory Bowel Disease

Crossref DOI link: https://doi.org/10.1007/s10620-018-5109-1

Published Online: 2018-05-14

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cohen-Mekelburg, Shirley https://orcid.org/0000-0001-5058-5527
Tafesh, Zaid

Coburn, Elliot

Weg, Russell

Malik, Neena

Webb, Colleen

Hammad, Hoda

Scherl, Ellen

Bosworth, Brian P.
Funding

Funding for this research was provided by:

National Center For Advancing Translational Science of the National Institute of Health (UL1TR000457)

Clinical and Translational Science Center at Weill Cornell Medical College (UL1-TR000457-06)
License Information

Text and Data Mining valid from 2018-05-14
More Information

Article History

Received: 8 July 2017

Accepted: 4 May 2018

First Online: 14 May 2018

Compliance with ethical standards

:

: E Scherl has received grant/research support from Abbott Laboratories (AbbVie), AstraZeneca, Janssen Research & Development, and Pfizer, and serves as a consultant to AbbVie, Janssen Pharmaceutical, and Takeda Pharmaceuticals. The other authors have no relevant conflicts of interest to disclose.